Aaron Wealth Advisors LLC Sells 1,706 Shares of Bristol Myers Squibb Company $BMY

Aaron Wealth Advisors LLC reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 1.9% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 89,229 shares of the biopharmaceutical company’s stock after selling 1,706 shares during the period. Aaron Wealth Advisors LLC’s holdings in Bristol Myers Squibb were worth $4,130,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in the business. Krilogy Financial LLC increased its position in Bristol Myers Squibb by 6.0% in the 2nd quarter. Krilogy Financial LLC now owns 11,592 shares of the biopharmaceutical company’s stock worth $537,000 after buying an additional 651 shares during the period. Fiduciary Alliance LLC increased its position in Bristol Myers Squibb by 209.8% in the 2nd quarter. Fiduciary Alliance LLC now owns 13,159 shares of the biopharmaceutical company’s stock worth $609,000 after buying an additional 8,912 shares during the period. Byrne Asset Management LLC increased its position in Bristol Myers Squibb by 72.0% in the 2nd quarter. Byrne Asset Management LLC now owns 2,148 shares of the biopharmaceutical company’s stock worth $99,000 after buying an additional 899 shares during the period. Czech National Bank increased its position in Bristol Myers Squibb by 6.7% in the 2nd quarter. Czech National Bank now owns 497,446 shares of the biopharmaceutical company’s stock worth $23,027,000 after buying an additional 31,344 shares during the period. Finally, Range Financial Group LLC increased its position in Bristol Myers Squibb by 6.0% in the 2nd quarter. Range Financial Group LLC now owns 55,280 shares of the biopharmaceutical company’s stock worth $2,559,000 after buying an additional 3,140 shares during the period. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on BMY. Wall Street Zen downgraded Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. Daiwa America lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Citigroup decreased their price objective on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, August 1st. Daiwa Capital Markets lowered Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a report on Tuesday, August 5th. Finally, Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $56.38.

Bristol Myers Squibb Trading Down 0.1%

BMY stock opened at $46.30 on Wednesday. The company has a market cap of $94.24 billion, a P/E ratio of 18.67, a PEG ratio of 2.37 and a beta of 0.35. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The business has a fifty day moving average of $47.06 and a 200-day moving average of $49.95.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. The company had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, equities research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.07% of the stock is currently owned by insiders.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.